{"name":"Omikron Italia S.r.l.","slug":"omikron-italia-s-r-l","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Citicoline eye drops 2%","genericName":"Citicoline eye drops 2%","slug":"citicoline-eye-drops-2","indication":"Dry eye disease","status":"phase_3"}]}],"pipeline":[{"name":"Citicoline eye drops 2%","genericName":"Citicoline eye drops 2%","slug":"citicoline-eye-drops-2","phase":"phase_3","mechanism":"Citicoline is a naturally occurring compound that enhances cell membrane phospholipid synthesis and promotes neuronal membrane repair and protection in ocular tissues.","indications":["Dry eye disease","Corneal dystrophy","Retinal degenerative diseases","Post-operative corneal healing"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQbk91SWw5cmEtMzhiRXhJNmRsVnpBaWhfcXg0T0h5Szh4Tm1zSGk0V1h1emxUcVRmaVgyczdpM1ZXXzJFYVBvWXRuNGpXckd1NjJzWmU0ZVFNMmpJSFl6dTFDR0I3Zzk0VURWZmo0bGl1Zl9hbHhOY1k3elhSNXlXM09HeDlMNk5mSFlZajQxSDctOGl5c0ZtYm9fbnZ6aEU?oc=5","date":"2026-04-03","type":"earnings","source":"openPR.com","summary":"Open Angle Glaucoma Market: Expanding Revenue Landscape to 2034 - openPR.com","headline":"Open Angle Glaucoma Market: Expanding Revenue Landscape to 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxOTlQzRkpQQlZDZXVlTFU3RzJWVV9HN3RhdWxyQ1gxdGJDaHFvZWpFQy1tOWRDbXhESDk2RkVWajdQZ2NhSTFncGlxTF9WTEVXMTdYZlhWdmd6NVI3b1FTbGdCZjNGTXBrVWp3S19GUF9DZlh0OFF3RXI0cU1XMFZhVXFzZjJZVkNpUU95bm9Jc0Y3Sm9yMkFoQ1dTTzNPb29PY0MwZ2VWaXJNR3d0WHgtY1BXV0FFWlMzZFRwdGl6VmR5U2xGMUNSLTRLdm9UQ2p6dVlvYU1BemYySTVLTE5va3ZFdmxvb0thRXNUNzlCVWJld0VuUDZn?oc=5","date":"2025-09-09","type":"pipeline","source":"PR Newswire","summary":"Open-Angle Glaucoma Market Outlook Brightens as Emerging Therapies Reshape Treatment Paradigms | DelveInsight - PR Newswire","headline":"Open-Angle Glaucoma Market Outlook Brightens as Emerging Therapies Reshape Treatment Paradigms | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxONzJwRzBpN1dGQ1h1QkRLdEFDQnRrcTJhMUkwSTJRdk9uZWJkVUZOd2VNel8tTWlJYzZkSzdJSG9nRXRuZFpkVFpEV1RKMDBvTWlkNnRaN3BzVUU5SWdZZDVwc1djWWhEaVhPRjlxWS15RDRJbm9hS29hQllqQktObGtUTDZ6OHlRQ2F4ZGlNQzFRUlpNakd2MkdiU244N3hLX3lka3FHS3VoTlVtbzJ2LXk2UHJ0ckZ5VjdGUi1MSUFRaU5YX2kxb2tOUnJoUFItM256NTFaaHhRSlpFRjdNVWE1eEZmY3RzdW5LZmZGcmI4dEVaNFlWcmZFQ3RXRVhfaGctMVhYTm9pdVMyaUx4ZC1feDh1SGk2czRLRUJzaDQydWVlWUdQUFR6bzJ5c09PaUtCWFNoQQ?oc=5","date":"2025-02-26","type":"pipeline","source":"GlobeNewswire","summary":"DURYSTA’s Market Potential Across the 7MM is Set to Soar - GlobeNewswire","headline":"DURYSTA’s Market Potential Across the 7MM is Set to Soar","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}